A rare lung nodule consisting of adenocarcinoma and amyloid deposition in a patient with primary systemic AL amyloidosis

Internal Medicine

Volumn 50, Issue 3, 2011, Pages 243-246

  Miyazaki, Daigo ^a   Yazaki, Masahide ^a   Ishii, Wataru ^a   Matsuda, Masayuki ^a   Hoshii, Yoshinobu ^b   Nara, Kenji ^c   Nakayama, Jun ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

Adenocarcinoma; AL amyloidosis; Lung nodule; Nephrotic syndrome

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; AMYLOID; BENCE JONES PROTEIN; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; VINCRISTINE;

ADULT; AMYLOIDOSIS; ARTICLE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; HUMAN; HYPOPROTEINEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY BIOPSY; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NODULE; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PRIMARY SYSTEMIC AL AMYLOIDOSIS; PROTEINURIA; RARE DISEASE; STOMACH BIOPSY; TUMOR VOLUME;

ADENOCARCINOMA; AMYLOID; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; COMBINED MODALITY THERAPY; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; KIDNEY; LUNG NEOPLASMS; MIDDLE AGED; PNEUMONECTOMY; STOMACH; TREATMENT OUTCOME; VINCRISTINE;

EID: 79551704513     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4094     Document Type: Article

References (20)

1. Gillmore JD, Hawkins PN. Amyloidosis and respiratory tract. Thorax 54: 444-451, 1999.
2. Paccalin M, Hachulla E, Cazalet C, et al. Localized amyloidosis: a survey of 35 French cases. Amyloid 12: 239-245, 2005.
3. Matsuda M, Yamada T, Gono T, et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 44: 428-433, 2005.
4. Hoshii Y, Setoguchi M, Iwata T, et al. Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 51: 264-270, 2001.
5. Matsuda M, Gono T, Katoh N, et al. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. Intern Med 47: 543-549, 2008.
6. Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic Experience from 1980 to 1993. Ann Intern Med 124: 407-413, 1996.
7. Ikeda S, Takabayashi Y, Maejima Y, et al. Nodular lung disease with five year survival and unilateral pleural effusion in AL amyloidosis. Amyloid 6: 292-296, 1999.
8. Gertz MA, Greipp PR. Clinical aspects of pulmonary amyloidosis. Chest 90: 790-791, 1986.
9. Yazaki M, Takei Y, Katoh M, Ikeda S. Postmortem findings in two familial amyloidosis patients with transthyretin variant Asp38 Ala. Amyloid 7: 270-277, 2000.
10. Miura K, Shirasawa H. Lambda III subgroup immunoglobulin light chains are precursor proteins of nodular pulmonary amyloidosis. Am J Clin Pathol 100: 561-566, 1993.
11. Merlini G, Bellotti V. Molecular mechanism of amyloidosis. N Engl J Med 349: 583-596, 2004.
12. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid 14: 179-183, 2007.
13. Jarret JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie. Cell 73: 1055-1058, 1993.
14. Van Nostrand WE, Melchor JP, Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem 70: 216-223, 1998.
15. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose malphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140: 85-93, 2004.
16. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 14: 261-269, 2007.
17. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tour, France, 18-22 April 2004. Am J Hematol 79: 319-328, 2005.
18. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 11: 245-256, 2004.
19. Sezer O, Schmid P, Schweigert M, et al. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 23: 967-969, 1999.
20. Zeier M, Perz J, Linke RP, et al. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant 18: 2644-2647, 2003.